Tag Archives: Tranexamic Acid

Severely Injured Trauma Patients With Admission Hyperfibrinolysis; Is There A Role Of Tranexemic Acid? (Lima)

Posted on by
Reply

Khan M, et al. Severely Injured Trauma Patients With Admission Hyperfibrinolysis; Is There A Role Of Tranexemic Acid? Findings From The PROPPR Trial. J Trauma Acute Care Surg. 2018 Feb 5. [Epub ahead of print]

INTRODUCTION: Administration of tranexemic acid (TXA) in coagulopathy-of-trauma (COT) gained popularity after the CRASH-2 trial. The aim of our analysis was to analyze the role of TXA in severely injured trauma patients with admission hyperfibrinolysis.

METHODS: We reviewed the prospectively collected Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) database. We included patients with admission hyperfibrinolysis (Ly30>3%) on thromboelastography. Patients were stratified into two groups (TXA and No-TXA) and were matched in 1:2 ratio using propensity score matching for demographics, admission vitals, and injury severity. Primary outcome measures were 6h, 12h, 24hr, and 30d mortality, 24-hour transfusion requirements, time to achieve hemostasis and re-bleeding after hemostasis requiring intervention. Secondary outcome measures were thrombotic complications.

Continue reading →

Does the use of tranexamic acid improve trauma mortality? (Petrillo)

Posted on by
Reply

Harvey V, Perrone J, Kim P. Does the use of tranexamic acid improve trauma mortality? Ann Emerg Med. 2013 Oct 3. doi:pii: S0196-0644(13)01341-3.

BOTTOM LINE: According to the available evidence, tranexamic acid has been shown to significantly decrease mortality in bleeding trauma patients, with no significant increase in serious prothrombotic complications if administered within 3 hours of injury. There is, however, no evidence of benefit in patients with traumatic brain injury. As such, we recommend early treatment with tranexamic acid in trauma patients without isolated brain injuries who have or are at risk for significant hemorrhage and in patients who receive resuscitation with blood products, particularly if they require massive transfusion or have a high risk of death at baseline.

Full-text for Children’s and Emory users.